Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262195 | 1.00 | CXCR2 (1.00) | CXCR2CXCR1 | |
| SCHEMBL12262265 | 1.00 | CXCR2 (1.00) | CXCR2CXCR1 | |
| SCHEMBL12262383 | 0.93 | CXCR2 (1.00) | CXCR2CXCR1 | |
| SCHEMBL12087202 | 0.93 | CXCR2 (1.00) | CXCR2CXCR1 | |
| SCHEMBL12086827 | 0.90 | CXCR2 (0.84) | CXCR2CXCR1 | |
| SCHEMBL12262259 | 0.90 | CXCR2 (0.84) | CXCR2CXCR1 | |
| SCHEMBL12576650 | 0.90 | CXCR2 (1.00) | CXCR2CXCR1 | |
| SCHEMBL12576517 | 0.90 | CXCR2 (1.00) | CXCR2CXCR1 | |
| SCHEMBL12576503 | 0.89 | CXCR2 (0.81) | CXCR2CXCR1 | |
| SCHEMBL12576505 | 0.89 | CXCR2 (0.81) | CXCR2CXCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1485089-B1 | COMBINATION TREATMENTS FOR CHEMOKINE-MEDIATED DISEASES | MERCK SHARP & DOHME (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | SCHERING CORPORATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7964646-B2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-06-21 | — | — | US | disclosed |
| US-7960433-B2 | Treatment of chemokine mediated diseases | SCHERING CORPORATION (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960433-B2 | Treatment of chemokine mediated diseases | SCHERING CORPORATION (US) | 2011-06-14 | — | — | US | disclosed |
| US-7947720-B2 | 3,4-di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2011-05-24 | — | — | US | disclosed |
| EP-1818325-B1 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORP (US) | 2010-02-24 | — | — | EP | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORPORATION | 2009-12-10 | — | — | US | disclosed |
| EP-1818325-A2 | 3,4-DI-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION (US) | 2007-08-15 | — | — | EP | disclosed |
| US-20070155756-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
| US-20070155756-A1 | Treatment of chemokine mediated diseases | SCHERING CORPORATION | 2007-07-05 | — | — | US | disclosed |
| EP-1381590-B1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | SCHERING CORP (US) | 2007-06-20 | — | — | EP | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155756-A1 | Treatment of chemokine mediated diseases | CXCR3, ACKR3, CCL11 | CXCR2 6/4885CXCR1 5/4885 |
| US-20110213029-A1 | 3,4-Di-Substituted Cyclobutene-1,2-Diones as CXC-Chemokine Receptor Ligands | CCR1, ACKR3, CXCR1 | CXCR2 7/4885CXCR1 3/4885 |
| US-20070021494-A1 | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands | CCR1, ACKR3, CXCR1 | CXCR2 7/4885CXCR1 3/4885 |
| US-20090306079-A1 | 3,4-DI-SUBSTITUTED CYCLOBUTENE-1,2-DIONES AS CXC-CHEMOKINE RECEPTOR LIGANDS | CCR1, ACKR3, CXCR1 | CXCR2 7/4885CXCR1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.